Phase 1 Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People must provide written consent to participate.
- For Arm 1, participants must be between 19 and 50 years old; for Arm 2, between 30 and 75 years old.
- Some participants in Group 2 must have a condition where the heart's left pumping chamber has become thickened and enlarged (Groups 2A and 2E).
- Some participants in Group 2 must have a diagnosed condition where the heart muscle becomes abnormally thick, making it harder for the heart to pump blood (Groups 2B and 2F).
- Some participants in Group 2 must be stable outpatients with a certain level of heart failure (rated class 1–3 on a standard medical scale) along with evidence of a thickened left heart chamber, regardless of how well the heart is pumping (Groups 2C and 2G).
- Some participants in Group 2 must have type 2 diabetes that is being managed with oral diabetes medication, with blood sugar control falling within a specific measured range (Groups 2D and 2H).
Who may not be able to join:
- People who have medical reasons preventing them from safely having an MRI scan or receiving MRI contrast dye.
- People in Group 2 whose red blood cell levels (haemoglobin) are too low, specifically at or below a certain threshold.
- People in Group 2 whose kidneys are not filtering blood well enough, based on a standard kidney function calculation (confirm with trial site).
- People who have any condition that means they are not expected to live longer than one year.
- People who have a medically diagnosed fear of enclosed spaces (claustrophobia).
- People who have received, or are scheduled to receive, another experimental medication within one month before or one month after joining this trial.
- People whose body weight relative to height (BMI) is below 18.5 or above 32.
- People in Group 1 who have a medically diagnosed heart condition.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Charles Cunningham, PhD, Sunnybrook Research Institute
Phone: 4164806100
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Ability of the MRI machine to produce an image of the participant's heart following an injection of Hyperpolarized Pyruvate (13C) as assessed by the physician
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.